TIL characteristics and clinical efficacy
| Patient | Site of biopsy | TILs cryo before REP | Y-TIL days in culture | Fold Expansion | Infused cells | BOR combined vem +TIL | BOR TIL | PFS (mo) | OS (mo) | |||
| Total (×109) | CD4% | CD8 % | CD8 (×109) | |||||||||
| 01 | SC | No | 34 | 2200 | 44 | 7.3 | 76.4 | 33.6 | SD | PD | 3.2 | 14.6 |
| 02 | SC | No | 20 | 4400 | 88 | 20.8 | 69.9 | 61.5 | PR | SD | 4.2 | 12.6 |
| 03 | SC | No | 21 | 4167 | 125 | 77.3 | 19.5 | 24.4 | CR (+) | CR (+) | 42.9+ | 42.9+ |
| 04 | LN | No | 21 | 2640 | 52.8 | 66.3 | 30.8 | 16.3 | PR | PR | 9.1 | 39.8 |
| 05 | SC | Yes | 13 | 4960 | 99.2 | 18.6 | 75 | 74.4 | PR | PR | 9.3 | 28.8 |
| 06 | SC | No | 29 | 4260 | 85.2 | 12.3 | 87.1 | 74.2 | PR | PR | 6.6 | 14.4 |
| 07 | LN | No | 34 | 2789 | 50.2 | 68 | 19.9 | 10 | PR (+) | PR (+) | 23.1+ | 24.7+ |
| 09 | SC | Yes | 28 | 3250 | 65 | 68.8 | 27.8 | 18.1 | PR | PR | 4.7 | 21.6+ |
| 10 | Lung | No | 26 | 1190 | 23.8 | 38 | 58 | 13.8 | PR | SD | 4.9 | 15.2 |
| 11 | SC | No | 13 | 4520 | 90.4 | 61.3 | 37.8 | 34.2 | SD | PD | 2.5 | 11.6 |
| 12 | SC/LN | Yes | 25 | 6160 | 123.2 | 5.4 | 94 | 115.8 | uPR | PD | 3.3 | 5.4 |
| 13 | SC | Yes | 19 | 5640 | 112.8 | 35.5 | 61.7 | 69.6 | SD | SD | 4.4 | 8.1+ |
| Median | 23 | 4213 | 86.6 | 36.8 | 59.9 | 33.9 | 4.8 | 15.2 | ||||
| Range | (13-34) | (2200–6160) | (23.8–125) | (5.4–77.3) | (19.5–94) | (10–115.8) | (3.2–42.9) | (12.6–42.9) | ||||
Plus signs (+) marks ongoing response or survival.
Patients highlighted in bold had further regression after TIL.
BOR, Best overall response according to Response Evaluation Criteria In Solid Tumors version 1.1; CR, complete response; cryo, cryopreserved; LN, lymph node; mo, months; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; REP, rapid expansion protocol; SC, subcutaneous; SD, stable disease; TIL, tumor-infiltrating lymphocytes; uPR, unconfirmed PR; vem, vemurafenib.